Comparative Pharmacology
Head-to-head clinical analysis: SAXENDA versus WEGOVY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SAXENDA versus WEGOVY.
SAXENDA vs WEGOVY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that increases insulin secretion, decreases glucagon secretion, delays gastric emptying, and promotes satiety via central GLP-1 receptor activation.
Semaglutide, a GLP-1 receptor agonist, increases insulin secretion, decreases glucagon secretion, delays gastric emptying, and reduces appetite via central GLP-1 receptor activation.
Subcutaneous injection once daily, starting at 0.6 mg and titrating weekly by 0.6 mg increments to a maintenance dose of 3.0 mg.
Subcutaneous injection 0.25 mg once weekly for 4 weeks, then increase to 0.5 mg once weekly for 4 weeks, then 1 mg once weekly for 4 weeks, then 1.7 mg once weekly for 4 weeks, then maintenance 2.4 mg once weekly.
None Documented
None Documented
11–13 hours (subcutaneous). Steady-state is reached after 3–5 once-daily doses.
Terminal elimination half-life is approximately 1 week (6–8 days), supporting once-weekly subcutaneous dosing.
Renal excretion of intact liraglutide is minimal; approximately 6% is excreted as intact liraglutide in urine. The remainder is metabolized and eliminated via the kidneys and feces, with no single metabolite accounting for >10% of the dose.
Primarily renal; approximately 97% of the dose is excreted unchanged in urine, with less than 3% in feces via biliary excretion.
Category C
Category C
GLP-1 Receptor Agonist, Anti-obesity
GLP-1 Receptor Agonist